NEXLIZET
Peakbempedoic acid and ezetimibe
NDAORALTABLET
Approved
Feb 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
NEXLIZET (bempedoic acid and ezetimibe) is adenosine triphosphate-citrate lyase inhibitors [moa]. First approved in 2020.
Drug data last refreshed 21h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEXLIZET is a fixed-dose combination tablet containing bempedoic acid and ezetimibe, approved in February 2020 for lowering cholesterol in patients with elevated lipid levels. It works through dual mechanisms: bempedoic acid inhibits ATP-citrate lyase (a key enzyme in cholesterol synthesis), while ezetimibe reduces dietary cholesterol absorption. This combination targets patients who require additional lipid-lowering therapy beyond statins.
$47MPart D
Peak13.7 years to LOEProduct is at commercial peak with moderate Medicare utilization; commercial teams should focus on market share defense as patent expiration approaches in 13.8 years.
Mechanism of Action
Adenosine Triphosphate-Citrate Lyase Inhibitors
Pharmacologic Class:
Adenosine Triphosphate-Citrate Lyase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NEXLIZET represents a stable, mature brand in the cardiovascular/metabolic space with no current job openings listed, reflecting its current steady-state commercial lifecycle. Career professionals joining this product would focus on defending market share against emerging competitors and preparing for eventual generic transition, with roles spanning sales, medical affairs, and strategic market access.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.